Calluna Pharma, CAL101, AURORA Study, Idiopathic Pulmonary Fibrosis, IPF, Phase 2 Clinical Trial, S100A4, Monoclonal Antibody, Pulmonary Fibrosis, Forced Vital Capacity,

OSLO, Norway, and BOSTON, Massachusetts — October 13, 2026 Calluna Pharma AS announced that all patients have completed dosing...